6489 LOGO20THELANSIS 26

The prevalence of MMA is estimated to be 1 in 50,000 to 100,000 in North America and at 1/26,000 in China. The pooled point estimates of the detection rates were 0.79, 1.12, 1.22, and 6.04 per 100,000 newborns in Asia-Pacific, Europe, North America, and MENA, respectively. In Europe, the highest estimated cases are being reported in Italy with 4.40/100,000 newborns cases in comparison to other EU5 countries

Read more:- Methylmalonic Acidemia (MMA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Methylmalonic-Acidemia-MMA-forecast

Comprehensive insight on patient segmentation based on forms (isolated MMA and combined MMA), Mutations (MUT, MMAA, MMAB, MMADHC, and MCEE ), severity level (Mild and Severe) has been provided into the epidemiology (Incidence & Prevalence) section of the Methylmalonic academia and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

KOL database for PMR

Moderna Therapeutics is leading the competitive pipeline for methylmalonic academia with a Phase II drug candidate (mRNA-3704). Apart from Moderna’s therapeutic candidate, there is not much activity in the clinical stages for this indication. However, there are several players like HemoShear Therapeutics, LogicBio Therapeutics, and Selecta Biosciences who are active in the pre-clinical space with their products. The innovative mechanisms being followed by pipeline therapies include gene expression stimulation, mTOR kinase inhibition; cyclin inhibition; protein kinase inhibition, and T cell inhibition

 

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-
Von Hippel-Lindau (VHL) disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Sonic hedgehog subtype of medulloblastoma (SHH MB) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Cutaneous Neurofibromatosis Type 1 – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Non-Tuberculous Mycobacterial (NTM) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Waldenstrom macroglobulinemia (WM) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: Methylmalonic Acidemia (MMA), Methylmalonic Acidemia (MMA) market outlook report, Methylmalonic Acidemia (MMA) competitive landscape, Methylmalonic Acidemia (MMA) market forecast